Gender Differences in Adipocyte Metabolism and Liver Cancer Progression

Otto K.-W. Cheung and Alfred S.-L. Cheng

1 School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, China, 2 State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China

Liver cancer is the third most common cancer type and the second leading cause of deaths in men. Large population studies have demonstrated remarkable gender disparities in the incidence and the cumulative risk of liver cancer. A number of emerging risk factors regarding metabolic alterations associated with obesity, diabetes and dyslipidemia have been ascribed to the progression of non-alcoholic fatty liver diseases (NAFLD) and ultimately liver cancer. The deregulation of fat metabolism derived from excessive insulin, glucose, and lipid promotes cancer-causing inflammatory signaling and oxidative stress, which eventually triggers the uncontrolled hepatocellular proliferation. This review presents the current standing on the gender differences in body fat compositions and their mechanistic linkage with the development of NAFLD-related liver cancer, with an emphasis on genetic, epigenetic and microRNA control. The potential roles of sex hormones in instructing adipocyte metabolic programs may help unravel the mechanisms underlying gender dimorphism in liver cancer and identify the metabolic targets for disease management.

Keywords: adipocyte, adipokine, adiponectin, epigenetic, gender dimorphism, hepatocellular carcinoma, leptin, metabolism

INTRODUCTION

Liver cancer is currently the third most common cancer type and the second leading cause of deaths in men (521,000, 6.4% of the total, per annum; Bray et al., 2013; Ferlay et al., 2015; GBD 2013 Mortality and Causes of Death Collaborators, 2015). Despite the use of aggressive treatments, the 5-years survival rate for patients with liver cancer only varies around 10% and will remain a global health concern, especially in Asian countries (Farazi and DePinho, 2006; Bray et al., 2013; Villanueva and Llovet, 2014). Hepatocellular carcinoma (HCC) has accounted for a majority (90%) of liver cancer cases. Risk factors leading to HCC comprise a medical history of chronic liver diseases, including liver cirrhosis, hepatitis, alcoholic and non-alcoholic fatty liver diseases (AFLD and NAFLD, respectively). NAFLD is characterized by abnormal accumulation of TAG in hepatocytes under metabolic and viral stimulation and it is reported to be one of the most prevalent causes of chronic liver diseases in Western countries, constituting an estimated prevalence of 20–40% (Tiniakos et al., 2010; Chalasani et al., 2012). NAFLD may progress into NASH, cirrhosis and ultimately HCC (Tian et al., 2013).

Emerging evidence has ascribed the development of liver cancer to obesity and type 2 diabetes (Welzel et al., 2013). The World Health Organization (WHO) categorizes a body mass index
(BMI) ≥ 25 kg/m² as overweight and a BMI ≥ 30 kg/m² as obese. From 1980 to 2008, the worldwide prevalence of obesity has doubled, according to the statistics of WHO (Finucane et al., 2011). Obesity does not only induce cancer-causing chronic inflammation, but also cause alterations in the endocrine system (Baffy et al., 2012; Vongsuvanh et al., 2012), which might altogether contribute to the increased risks for the development of NAFLD and HCC (Vanni and Bugianesi, 2014; Chang et al., 2016). Due to the difficult differentiation in a large scale, separate global estimates of prevalence for types 1 and 2 diabetes are not available (NCD Risk Factor Collaboration [NCD-RisC], 2016). The skyrocketing increase in the number of diabetic patients estimated by WHO (fourfolds) from 1980 to 2014 has coincided with the current increase of liver cancer incidence (NCD Risk Factor Collaboration [NCD-RisC], 2016). Indeed, a recent study has as well estimated that patients with a history of diabetes and/or obesity will exhibit a 2.47-fold higher liver cancer risk (Welzel et al., 2013). The present epidemic of fat-associated metabolic syndromes is positively correlated to the increasing trend of HCC all over the world.

Sexual dimorphism is the biological inequality between males and females in disease initiation and progression. Deregulated signaling of sex hormones, i.e., androgen in males and estrogens in females, is believed to be one of the drivers of sexual dimorphism in HCC. The male-to-female ratio averages between 2:1 and 7:1 in virus and NAFLD-related HCCs (Parkin et al., 2006; Guerrero et al., 2009; El-Serag, 2012; Tian et al., 2013). Recent population-based studies have consistently demonstrated much higher risk of HCC in obese men. In a prospective study including more than 900,000 adults, it was found that men with a BMI of 35 kg/m² exhibited a dramatic 4.52-fold increase in relative risk of death from liver cancer, while a modest 1.68-fold increase was observed in women (Calle et al., 2003). A cohort study of 5.24 million adults in UK has further confirmed the significant modulation of HCC incidence by gender (Bhaskaran et al., 2014). More recently, a multi-ethnic cohort study has shown that BMI was strongly associated with HCC in Japanese, white, and Latino men (Bhaskaran et al., 2014). The multi-regional epidemiological studies have all revealed the high male-to-female ratio in both HCC incidents and risks, raising a question in how two genders differ in the pathogenesis of HCC.

While NAFLD-associated HCC is closely associated with deregulation in fat metabolism, gender dimorphisms may occur in our adipose homeostasis. Differences in body fat composition rather than BMI were suggested to be true determinants of HCC prognosis. Indeed, visceral adiposity can independently predict mortality in patients with HCC (Setiawan et al., 2016). Coincidentally, visceral fat accounts for a strikingly larger proportion of body fat in men than in women, indicating the potential importance of the studies into HCC-associated fat metabolism and the corresponding gender disparities (Fujiwara et al., 2015; Setiawan et al., 2016).

Current studies in the gender disparities in HCC primarily focus on the deregulated signaling pathways and metabolism in hepatocytes. While abnormal fat metabolism plays a crucial role in the onset of HCC, the dramatic differences in the body fat distribution and the adipocyte depot-specific roles in different genders are seldom taken into account. We are presenting the current understanding of the gender disparities in the body fat composition and glycerol metabolism, and discuss the mechanisms by which these metabolic alterations potentially contribute to the contrasting number of incidents of HCC in males and females.

### ADIPOCYTE METABOLISM AND HCC

Metabolic syndromes are closely associated with two types of white adipose tissues, visceral adipose tissue (VAT) and subcutaneous adipose tissue (SCAT). Gender disparities occur in the distribution and composition of body fat, which may help explain the cause for the strikingly higher HCC incidence in men. VAT differs from SCAT in terms of anatomy, cellular functions, molecular compositions, endocrine functions, and their response of insulin and other hormones. Anatomically, VAT and SCAT are categorized by their corresponding location of depots. Visceral fat is defined as the fat depots around the abdominal organs including the liver and the small intestine; subcutaneous fat, which is located at the femerogluteal regions, back and anterior abdominal wall, represents the physiological buffer for excess energy intake and accounts for around 80% of our total body fat (Wajchenberg, 2000). Visceral fat accumulates as the age increases in both genders (Wajchenberg, 2000). As mentioned, men possess nearly 30% more visceral fat than women, suggesting the promising field to study in resolving the relationship among adipocyte physiology, genders and HCC. (Fujiwara et al., 2015; Setiawan et al., 2016). Regarding their particular locations, visceral fat and subcutaneous fat employ different drainage routes of blood. Venous blood from VATs is circulated directly to the liver via the portal vein while subcutaneous fat venous blood is drained through systemic veins (Klein, 2004). Adipocytes are responsible for the storage of excess energy intake and the absorption of free fatty acids (FFAs) and triglycerides. Adipocytes get dysfunctional when they get hypertrophic (Ibrahim, 2010). Adipocytes in VAT are generally bigger in size, hyperlipolytic, insulin-resistant and are molecularly different from those in the subcutaneous regions (Ibrahim, 2010). The accumulation of visceral fat in the omental region promotes insulin resistance and its associated liver injury. The deregulated release of FFAs and glycerol from visceral adipocytes can also contribute to the onset of HCC. Considering the fact that visceral fat accumulates more in males and it causes a tumor-promoting condition in the liver, it is logical to postulate the intriguing relationship between fat metabolism and the gender dimorphisms in HCC.

The adipose tissue comprises multiple cell lineages including adipocytes, preadipocytes, vascular and neural cells and more importantly the immune cells (Ibrahim, 2010; Gregor and Hotamisligil, 2011). Early studies reported the increase in infiltration of inflammatory macrophages in VAT, which thus causes insulin resistance in mice and human (Weisberg et al., 2003; Bruun et al., 2005; Michaud et al., 2012). C-C motif chemokine receptor 2-knockout (Ccr2-KO) mice attributed insulin resistance in diet-induced obesity to the shift of from
pro-inflammatory M1 macrophages into alternatively activated M2 macrophages and the reduction of anti-inflammatory cytokine interleukin-10 (IL-10) (Lumeng et al., 2007). The increased infiltration of inflammatory macrophages in visceral fat causes insulin resistance via the nuclear factor-kB (NF-kB) pathway (Lè et al., 2011). In general, visceral fat accumulation is accompanied with the increase in M1 macrophage population, nurturing an elevated local inflammation and a pro-carcinogenic environment within the adipose tissue. The accumulation of activated M2 macrophages in the abdominal adipose tissue remove the protective effect of IL-10 against tumor formation. The increased infiltration could also elevate the liver burden and gradually promotes HCC.

Both levels of visceral fat and HCC risks positively correlate with age and a masculine gender. In view of the harmful effects of visceral adiposity, the contrasting levels of visceral fat accumulation in males and females may help explain the gender disparities in immune responses (Klein and Flanagan, 2016) and HCC development (Tian et al., 2013).

**Visceral Adipose Tissue and HCC**

Obesity is a heterogeneous disorder, with which obese individuals exhibit a wide range of body fat distribution and the associated metabolic profiles. Obesity is associated with excess body fat. Adipose tissue has long been considered as an inert storage of energy while more recent studies have pointed out its role in the immune and endocrine regulation (Cabia et al., 2016). White adipose tissue can be subdivided into VAT and SCAT according to its distribution. VAT mainly deposits around the abdominal viscera in mesentery and omentum and is responsible for the “central obesity” phenomenon in which individuals have a greater risk of type 2 diabetes, cardiovascular diseases and obesity-related cancer (McKeigue et al., 1991; Pérez-Pérez et al., 2009; Ibrahim, 2010; Wolin et al., 2010). VAT and SCAT present very distinct physiological functions. VAT acts as a metabolically active endocrine organ secreting a number of adipokines for regulatory purposes (Ibrahim, 2010). Visceral adiposity has been complicated with negative effects including insulin resistance and the elevated production of pro-inflammatory molecules leptin (LEP), resistin, tumor necrosis factor-α (TNF-α), IL-6, hypoxia-inducible factor 1 (HIF-1) and adipocyte fatty-acid binding protein (A-FABP) (Weisberg et al., 2003; Wisse, 2004; Gregor and Hotamisligil, 2011; Spoto et al., 2014; Petrangeli et al., 2016). Excess absorption of fat from the diet enlarges adipocytes and stimulates the release of FFAs (Ibrahim, 2010) (Figure 2). Visceral fat is considered as a major source of FFAs in the portal vein, which can cause liver fat accumulation and the development of NAFLD (Paschos and Paletas, 2009). Adiposity has also been reported to associate with cancer-causing phenotypes including secretion of immune cell-attracting molecules (e.g., monocyte chemoattractant protein 1, MCP-1), angiogenesis, cellular senescence through microbial metabolites (e.g., deoxycholic acid, DCA), lipolysis and decreased production of adiponecin (Yu et al., 2006; Bruemmner, 2012; Duan et al., 2013; Ferrente, 2013; Yoshimoto et al., 2013) (Figure 2). FFAs-induced inflammation and insulin resistance leads to pathogenic endoplasmic reticulum stress and eventually fosters a tumor-promoting, low-grade chronic inflammatory microenvironment in the liver (Ohki et al., 2009; Zhao and Lawless, 2013). A particular form of FFAs, linoleic acid, which is usually accumulated in NAFLD, has recently been ascribed to the disruption of mitochondrial function, oxidative damage and the selective loss of intrahepatic CD4+ T cells (Ma et al., 2016). Adiposity is closely associated with the immune cell population in liver. Alongside the chronic inflammation caused by the increase in FFA release, the loss of CD4+ T cells potentially results in the failure of recruiting innate immune cells to kill pre-malignant senescent hepatocytes and suggesting the role of an inflammatory microenvironment in HCC initiation. An increased population of B lymphocytes was found recruited in adipose tissue in obese subjects (Figure 2). B cells in obese mice favored the secretion of pro-inflammatory cytokines IL-6 and suppressed anti-inflammatory cytokines IL-10 (Winer et al., 2011). High-fat diets raised B cell population and caused insulin resistance in mice (Winer et al., 2011). VAT accumulation has also been proposed as an independent risk factor for HCC since visceral fat accumulation was positively correlated to the recurrence of HCC and the severity of fatty liver in NAFLD patients, but, interestingly, not SCAT (Ohki et al., 2009). Cohort studies using computerized tomography (CT) to measure VAT have shown that visceral fat accumulation enhances the severity of hepatic inflammation and fibrosis in NASH, HCC risks as well as the recurrence of HCC after curative treatment (van der Poorten et al., 2008; Ohki et al., 2009; Vongsuvanh et al., 2012; Schlesinger et al., 2013). Furthermore, visceral fat accounted up to 10–20% of the total fat in men and 5–8% in women, whereas subcutaneous fat accounts for a significantly larger portion of total body fat in women as shown in different studies (Bhaskaran et al., 2014; Setiawan et al., 2016) (Figure 1). Emerging evidence in visceral fat accumulation points toward tumor formation and the differential body fat composition in males and females potentially results in gender disparities in HCC risks. The higher level of metabolically active VAT in males nurtures a pro-carcinogenic environment while the higher SCAT level in females may, on the other hand, offers a buffering and protective effect against HCC formation. Regarding the tumor-promoting properties of visceral fat and the coinciding gender dimorphisms in both liver cancer and visceral adiposity, the following session will focus on the underlying mechanisms (Figure 2).

In short, the higher level of VAT in males contributes to the likelihood of HCC initiation either by releasing pro-inflammatory adipokines, metabolites or immune cell infiltration.

**Adipokines and HCC**

Adipokines are peptides, proteins, and cytokines synthesized by the adipose tissue. Over 75 adipokines have been identified in adipose tissue, while only some of them are associated with carcinogenesis, especially the development of liver cancer (Trayhurn and Wood, 2004; Wood et al., 2009; Zhao and Lawless, 2013; Cabia et al., 2016). Classical examples of adipokines synthesized by dysfunctional obese adipose tissue are usually involved in localized chronic inflammation. Enlarged adipocytes in VAT liberates FFAs to stimulate adipose tissue macrophages...
FIGURE 1 | Gender dimorphism occurs in the altered metabolic pathways that can lead to the progression of HCC. Visceral adiposity can be observed more commonly in men and nurtures a pro-carcinogenic microenvironment that promotes HCC initiation.

FIGURE 2 | Visceral adiposity increases the release of pro-inflammatory adipokines and reduces the protective counterpart, causing immune cell infiltration, liver injury, and the subsequent pathological syndromes. The increase in the release of FFAs and glycerol to the liver from visceral fat also promotes lipid peroxidation and thus increases HCC risks. MDSCs: myeloid-derived suppressor cells.
to produce TNF-α, which in turns activate adipocytes to undergo lipolysis and secret multiple cancer-causing adipokines (Ibrahim, 2010; Michaud et al., 2012). MCP-1 is secreted by adipocytes to recruit macrophages and myeloid-derived suppressor cells (MDSCs) to local tissue and further worsen chronic inflammation (Yu et al., 2006; Okwan-Duodu et al., 2013) (Figure 2). Moreover, hypertrophied adipocytes are exposed to a hypoxic condition in which there is an elevated production of HIF-1, leading to the infiltration of macrophages and the secretion of adipokines (Trayhurn et al., 2008) (Figure 2). The release of a pro-inflammatory cytokine IL-6 from hepatic stellate cells is associated with an increased level of FFAs in VAT (Wieckowska et al., 2008; Yoshimoto et al., 2013). IL-6 is also associated with insulin resistance, fibrosis and tumorigenesis involving the activation of STAT3, Akt, Erk, JNK pathways (Wieckowska et al., 2008; Park et al., 2010).

Leptin is an important adipose-derived hormone involved in energy homeostasis, immune responses, angiogenesis, and insulin signaling (Franckhauser et al., 2006). Leptin overexpression was found responsible for TNF-α and IL-6-related chronic inflammation, insulin resistance, liver fibrosis, and HCC development (Ikejima et al., 2001; Wang et al., 2001; Franckhauser et al., 2006; Chen et al., 2007; Tsochatzis et al., 2008). Leptin has been reported to cause proliferation of HCC cells by altering the activity of cyclin D1 and the apoptotic gene, Bax (Chen et al., 2007). Leptin is also one of the reported biomarkers for early recurrence of HCC after treatment (Watanabe et al., 2011). Women require twice as high circulating leptin levels to maintain normal body weight and are more resistant to leptin activity than men do (Licinio et al., 1998). The resistance to leptin in women potentially reduces the corresponding harmful effects. A reduction in leptin sensitivity may reduce cytokine-induced inflammation and insulin resistance. It is suggested that women are subject to a lower HCC risk due to a lower sensitivity to leptin.

Adiponectin is considered to play a protective role in cancer progression involving anti-inflammation, sensitization of insulin signaling and anti-angiogenesis. Adiponectin induces the production of IL-10, working together to inhibit inflammatory factors like IL-6 by inhibiting the NF-κB pathway cascade (Ibrahim, 2010; Lira et al., 2012). Other anti-cancer mechanisms of adiponectin include promoting apoptosis in HCC cells and inhibit cell migration by inhibiting Akt/STAT3 signal transduction (Sharma et al., 2010; Lira et al., 2012). Contradictory results showed the cancer-promoting role of adiponectin in HCC patients. A significantly higher level of serum adiponectin is reported in HCC patients and was also found guilty for tumor growth (Chen et al., 2012; Sadik et al., 2012). Since the metabolic profiles in HCC patients have been severely altered, the implicit role of adiponectin regarding HCC development requires further investigations. Despite all these, it is generally believed that men with a higher level of visceral fat accumulation are more subject to a procarcinogenic microenvironment. Hormonal influences on adipocyte homeostasis could be one of the reasons for the differential visceral fat accumulation and the differences in adipokine production.

**GENDER DIMORPHISM IN ADIPOCYTE METABOLISM**

**Sex Hormones and Adipocyte Metabolism**

Visceral fat deposition is significantly higher in males than in females whereas subcutaneous fat accumulates more in females (Ibrahim, 2010). Having a similar total fat and BMI, males showed a higher visceral fat and liver fat content than females in multiple datasets (Bhaskaran et al., 2014; Setiawan et al., 2016). Obvious gender dimorphism was also observed in both diet-related liver diseases and HCC initiation (Chang et al., 2016). Visceral fat actively secrets oncogenic adipokines, leading to chronic inflammation and contributes to liver cancer. The disparities of liver cancer and visceral fat deposition potentially originate from high androgen receptor (AR) density (Freedland, 2004). The increase in body visceral fat and the decrease in body subcutaneous fat as the age increases, coinciding with the increase with HCC incidence (Björntorp, 1995). Estrogen promotes the accumulation of subcutaneous fat and is protective against inflammation (Ibrahim, 2010). After menopause, the rise of body VAT in women is related to the deficiency of estrogen (Björntorp, 1995; Freedland, 2004). Signaling pathways involving sex steroids contribute to the differential secretion of cancer-causing adipokines in men and women, thus leading to a higher risk of HCC in men. Potential sexual dimorphism in HCC is also caused by the differential recruitment of Foxa-1/2 transcription factors and the corresponding androgen and estrogen receptors, showing the involvement of steroid hormones in liver cancer development (Li et al., 2012). AR and ER can both act as transcription factors altering chromatin accessibility and gene transcription in HCC (Li et al., 2012). Although limited studies using chromatin-immunoprecipitation-sequencing (ChIP-seq) have been done on adipocytes, it is postulated that the differential binding profiles of AR and ER in visceral fat and subcutaneous fat can help unveil the underlying mechanisms of androgen and estrogen in visceral adiposity and the subsequent side effects. The potential links may help understand the differences of adipokine profiles in men and women and thus explain how men get more prone to HCC initiation.

**Estrogen**

Estrogen and estrogen receptor (ER) signaling have been found to have a protective role in HCC initiation and progression via the IL-6/STAT inflammatory pathways (Naugler et al., 2007; Yang et al., 2012). One of the anticancer adipokines adiponectin is expressed at a higher level in women than in men (Laughlin et al., 2006). Estrogen replacement therapy helps decrease adiponectin circulation in postmenopausal women (Kunnari et al., 2008). It is reported that adiponectin is inversely associated with the incidence of multiple types of diet-related cancer (Housa et al., 2006). Adiponectin is associated with anti-inflammation, increasing insulin sensitivity and anti-angiogenesis, which coincides with the protectively role of estrogen signaling (Tworoger et al., 2007; Ibrahim, 2010). A reduction of body estrogen after menopause is frequently
followed by an increase in body visceral fat (increase in size of adipocytes), hyperinsulinemia and increase in IL-6 production (Freedland, 2004). Estrogen offers a protective effect against metabolic deregulation and HCC. It is suggested that a reduction in the endogenous estrogen level causes a drop in adiponectin in postmenstrual women. The physiological mechanisms of estrogen on the release of adiponectin are a potential explanation for the gender dimorphism of HCC.

Androgen
Regional androgen concentration in VAT suggests a depot-specific effect on adipocyte functions and metabolism (Bélanger et al., 2006). Androgen excess in female mice using 5α-dihydrotestosterone (DHT) treatment induced an increase in visceral fat deposition, via an altered hypothalamic axis (Nohara et al., 2014). The complicated role of androgen signaling in body fat distribution and adipocyte functioning has long annoyed scientists for decades. Early studies revealed results on a reduced circulating androgen levels with visceral fat deposition (Garaulet et al., 2000; Tsai et al., 2004; Kraus et al., 2015). Androgen was shown to have a suppressive effect in adiponectin level consistently in cell lines, animal models, and human epidemiological studies (Nishizawa et al., 2002; Lanfranco et al., 2004; Isobe et al., 2005; Page et al., 2005). Such phenomenon explains how androgen undermines the anti-inflammatory effects of adiponectin and develops chronic inflammation in the liver. Regarding the regulation of androgen on genes involved in adipogenic genes, recent studies have discovered the role of microRNA miR-375 in adipocyte differentiation and distribution. Androgen treatment in preadipocytes could downregulate miR-375 expression and increase the level of adiponectin receptor 2 (ADIPOR2), which might help understand the mechanisms of how testosterone deficiency could lead to insulin resistance and visceral fat accumulation (Kraus et al., 2015). Generally, visceral fat has a high density of AR, which allows testosterone to amplify its own effect by raising AR expression, inhibiting lipoprotein lipase and the uptake of FFAs (Wajchenberg, 2000; Freedland, 2004). As men age, the bioavailability of testosterone declines and leads to the deposition of visceral fat. Yet, the case is opposite in women who exhibit an increase in androgen level released from the ovary when they are complicated with hyperinsulinemia and it is known as the polycystic ovary syndrome (Wajchenberg, 2000; Freedland, 2004). In vivo and in vitro studies of leptin production varied greatly. Adipocytes from different locations reacted differently to androgen in vivo and in vitro (Machinal et al., 1999). The difficulty of local application of androgen has long limited the physiological studies of how androgen affects a particular region of adipocytes and the following pathologies. Contrary to its involvement in HCC, androgen appears to inhibit visceral fat accumulation and the complicated association among androgen, visceral fat accumulation and liver cancer needs further investigation.

In short, the androgen to estrogen ratio determines the leptin and adiponectin levels and visceral adiposity. A higher androgen to estrogen ratio is associated with a respective higher leptin and lower adiponectin ratio in both genders. The high androgen to estrogen ratio is linked to metabolic syndromes and it is also predicted such phenomenon is one of the culprits for HCC initiation.

Gender-specific Single Nucleotide Polymorphisms in Adipose Tissue
The large discrepancies in fat distribution and homeostasis in males and females imply potential genetic predispositions. Single nucleotide polymorphisms (SNPs) are enriched for expression of loci of quantitative traits and may alter gene expression (ENCODEx Project Consortium, 2012). This mechanism has been argued to be a major driver in disease susceptibility by genetically altering the susceptibility of DNA methylation and thus affecting gene expression (Martínez et al., 2014). It has been demonstrated for obesity, insulin resistance, inflammation, oxidative stress, and hypoxia, which are all driver components of HCC initiation (Martínez et al., 2014). Such mechanism is also reported to be cell type-specific (Fairfax et al., 2012). Sex-specific SNPs are found potentially responsible for fat distribution and inflammation (Sung et al., 2016; Wang et al., 2016). Martinez et al. (2014) have summarized a panel of candidate genes which are epigenetically regulated through DNA methylation and are involved in lipid homeostasis, including CEBPA, PPARA, LEP, MC4R, NPY, POMC, FTO, ADIPOQ, GLUT4, INS, HIF1α, IFNG, TNF, FAS, NR3C1, and UCP1 (Martínez et al., 2014). Among all the epigenetic targets, sexual dimorphisms in the SNPs can be identified, including the Adiponectin, C1Q And Collagen Domain Containing gene (ADIPOQ) and the leptin gene (LEP), which, respectively, encode for crucial players in visceral adiposity and liver cancer initiation, adiponectin and leptin (Figure 3).

ADIPOQ
ADIPOQ has a length of 1.579 kb and contains three exons, in which the transcription start site is located at exon 2 (Mackevics et al., 2006). Several SNPs inside the ADIPOQ gene have been associated with adiponectin serum levels, body adiposity and other metabolic alterations, rendering it a potential player in obesity and metabolic syndromes (Mackevics et al., 2006; Dolley et al., 2008; Bostrom et al., 2009). Association studies of ADIPOQ polymorphisms, adiponectin levels and obesity phenotypes using samples of African American population from the Jackson Heart Study (JHS) cohort (Riestra et al., 2015). Data collected from 2968 participants (1131men and 1837 women) revealed gender-specific association between SNPs rs6444174, rs1403697, and rs7641507 with serum adiponectin levels in women but not men (Riestra et al., 2015). SNPs in ADIPOQ have also been reported to be associated with type 2 diabetes (Peters et al., 2013). SNPs at the adiponectin gene appear differently in men and women affecting circulating adiponectin, which may cause different adipocyte homeostasis and thus affecting the liver functions in a sex-specific manner.

Leptin (LEP)
DNA polymorphism in the leptin gene is associated with tumorigenesis of multiple cancer types, such as lung cancer, lymphoma, thyroid cancer, and colon cancer (Slattery et al., 2008; Liu et al., 2014; Unsal et al., 2014; Marcello et al., 2015).
**FIGURE 3** | Protective single nucleotide polymorphisms (SNPs) in ADIPOQ and LEP genes that lead to differential serum adiponectin and leptin levels occur frequently in females. A respective higher adiponectin and a lower leptin level can be found in female subjects. SNPs in ADIPOQ and LEP genes potentially reduce HCC risks and development in women through inflammatory and oncogenic pathways.

**LEP** is primarily expressed in differentiated adipocytes of white adipose tissue, and the hormone leptin it encodes for, plays a role in the regulation of food intake and the expression of energy-regulating peptides. **LEP** has been proposed as a culprit for obesity-induced cancer because it displays epigenetic variation and is involved in energy homeostasis, immune responses, angiogenesis and insulin signaling (Franckhauser et al., 2006). Deregulated production of leptin or its receptor is highly associated with HCC development (Chen et al., 2007). Some Leptin G-2548A (rs7799039) polymorphism showed association with serum leptin level and obesity in young females only (Ben Ali et al., 2009; Shahid et al., 2015) (Figure 3). Since leptin is closely related to insulin signaling and inflammation, it is considered as a strong risk factor in obesity-related cancer. The gender dimorphism in the leptin gene may alter leptin secretion in adipocytes and eventually alter the cancer risk in different genders (Tobi et al., 2009). On the other hand, when the preadipocytes mature, the gene is activated by DNA demethylation (Melzner et al., 2002). Differences in the methylation status of the **LEP** promoter influence **LEP** expression in vitro, which approves the functional role of DNA methylation on leptin secretion in adipocytes (Rankinen et al., 2006). The establishment of epigenetic profiles is susceptible to maternal diets during early development (Dahlhoff et al., 2014). Female mice undertaking high-fat diets affected the offspring genes involved in fatty liver disease, lipid droplet size regulation and body fat expansion (Dahlhoff et al., 2014). The harmful effects of maternal diets on offspring have been reported to be organ-specific, gender-specific and remain at different life stages. The adult male offspring exhibited traits related to liver disease development overweight, insulin resistance, high leptin levels and hepatic steatosis but not the female counterpart, proving the possibility of gender-specific expression of leptin (Dahlhoff et al., 2014; Ge et al., 2014; Allard et al., 2015) (Figure 4).

Single nucleotide polymorphisms in the genes controlling expression of key adipokines leptin and adiponectin exert differential effects on males and females. Metabolic syndromes including type 2 diabetes and excess fat deposition could be caused by the differential expressions of **ADIPOQ** and **LEP** genes in males and females as a result of the respective SNPs.

GWAS studies rely heavily on the associations of gender-specific SNPs with metabolic traits such as insulin, leptin, adiponectin levels to support the fact that certain genetic predispositions leading to visceral fat accumulation and the release of leptin increases the risks of metabolic complications. The following challenge now is to understand the biological functions of those genes and how they are regulated differentially in males and females. In the aspect of genetics, mRNA expression profiles of such genes can be correlated with BMI, body fat distribution and our gender. Other possible mechanisms include epigenetic regulation via DNA methylation or histone modifications may be responsible for the association of the aforementioned traits with gender.

**Epigenetic Regulation in Adipose Tissue**

Epigenetic regulation of genes are considered to be important for disease pathogenesis since it is believed to translate...
FIGURE 4 | Hypermethylation of LEP promoter in female offspring offers a protective effect against maternal high-fat diets by lowering leptin production in mice. Maternal high-fat diets affect offspring's epigenetic regulation on the LEP gene. Obesogenic environments during the pre-conceptional period and the early phase of development led to a lower methylation state of the LEP promoter in male rodent offspring than their female counterparts. The higher leptin production in male offspring was also associated with overweight, insulin resistance and hepatic steatosis, which could help explain the gender dimorphism in leptin production and the development of liver diseases and HCC.

environmental factors into phenotypic traits through alteration in the transcriptome (Fraga et al., 2005; Sandovici et al., 2011).

DNA Methylation

One of the many epigenetic mechanisms, methylation of CpG dinucleotides is proved to play crucial roles in the decision of cell fates, tumorigenesis and multiple cellular functions (Esteller, 2007; Baylin and Jones, 2011). DNA methylation usually occurs at CpG-rich regions and is often associated with gene repression (Bird, 2002). Epigenetics can provide insights for the understanding of chronic disease onset in adults, which interact with external stimuli like dietary intake and nutritional processes. Epigenetic regulations are believed to translate physiological impacts into altered gene expressions. Many genomic studies have reported the gene expression patterns in VAT, yet the differentially expressed genes may be functionally associated with visceral fat dysfunction and metabolic syndromes, including adipose tissue macrophage-specific genes and insulin resistance-related genes (Bouchard et al., 2007; Blüher, 2009; Hardo et al., 2011; Klimcakova et al., 2011). Epigenetic mechanisms may contribute to the variability of the gene expression and the different components of metabolic syndromes. Transcriptional CpG-island promoter hypermethylation or global DNA methylation may affect the expression of genes controlling adipokine secretion, fat distribution, macrophage infiltration and insulin sensitivity. A recent genome-wide analysis of CpG methylation states of blood and adipose tissue from 479 individuals has revealed the association between DNA methylation and BMI (Dick et al., 2014). Data showed that the methylation level at three HIF3A sites was strongly correlated to BMI in adipose tissue, i.e., an increase in BMI was associated with an increase in methylation level at HIF3A sites. The HIF3A gene could not only respond to oxygen content locally, but it also played a role in cellular response to insulin and glucose and accelerated adipocyte differentiation in acquired obesity (Heidbreder et al., 2007; Hatanaka et al., 2009; Robciuc et al., 2011). Obesity has been reported to increase a global mean DNA methylation in adipocytes (Arner et al., 2015; Benton et al., 2015). Exercise can significantly influence the DNA methylation patterns in a genome-wide manner (Rönn et al., 2013). Post-obese patients experienced a global DNA hypomethylation and differential methylation of adipogenesis genes (Dahlman et al., 2015). More DNA methylation in adipocytes can regulate different genes related to hypoxia and insulin sensitivity, providing a new scope for investigating the relationship between adipocyte homeostasis and liver cancer development.

Recent studies have also take advantage of cell lines and human mesenchymal stem cells in the study of DNA methylation in the transcriptional activation of leptin and adiponectin genes (Kuroda et al., 2016; Zhang W. et al., 2016). On top of this, Ambati et al. (2016) have also demonstrated the differential expressions of genes encoding for epigenetic regulators in VAT and SCAT in mice. The adipocyte nuclei were immuno-captured from VAT and SCAT to resolve the difficulties of isolating mature adipocytes from adipose tissue. The differential expressions of chromatin remodeler proteins involved in DNA methylation and histone modification shed light on the studies of epigenetic regulation of gene expressions in adipose tissues, promoting the study in the gender disparities in adipocyte homeostasis through...
epigenetics. Possible mechanisms of such disparities may include the binding of transcription factors like AR and ER alongside other pioneer factors that affect the chromatin status (Iwafuchi-Doi et al., 2016).

Histone Modifications
Histone modifications represent another important mechanism of epigenetic regulation (Baylin and Jones, 2011). Histone acetyltransferases (HATs) and histone deacetylases (HDACs) have been shown to respond to regulatory signals involved in adipocyte differentiation and adipogenesis (Zhou et al., 2014). HDAC9 negatively regulated adipogenic differentiation in HDAC9 overexpression and knockout experiments (Chatterjee et al., 2011). During chronic high-fat feeding in mice, HDAC9 deletion was shown to offer a protective effect against metabolic diseases by increasing adiponectin expression (Chatterjee et al., 2014). Histone deacetylase HDAC4 is repressed in exercise-induced DNA methylation, leading to a reduced repressive activity on glucose transporter GLUT4 and thus increasing adipocyte glucose uptake and lipogenesis (Rönn et al., 2013). Recent studies have also shown the effect of H3K9 methylation at Cebpα and Pparg loci marked with H3K4me3 deposition limits CCATT/enhancer binding protein β binding and thus halting adipogenesis (Matsumura et al., 2015). Although very limited studies have been done on histone modification profiling in adipocytes, more and more evidence is pointing toward the roles of histone modifiers in adipocyte functions the pathological development of metabolic diseases. Epigenetic studies of adipocyte metabolism may shed light on the disease progression as well as the gender differences in metabolic diseases and HCC.

Gender Dimorphism in MiRNAs Actions in Adipocyte Tissue
MicroRNAs (miRNAs) are small noncoding RNAs of 18–15 nucleotides that regulate the translation of messenger RNAs (mRNAs) through binding to their 3' untranslated regions (UTRs) leading to translation inhibition and/or mRNA degradation (Wong et al., 2008). miRNAs are known to be involved in multiple biological functions, including cell proliferation, cell differentiation, metabolism, and immunity and in diseases such as cancer, cardiovascular diseases and type 2 diabetes (Mendell, 2005). In adipocytes, the expression of miRNAs and the corresponding regulation are closely related to sex hormones androgen and estrogen, providing a promising scope to understand gender dimorphism in lipid metabolism.

miR-125a/b
The miR-125 family comprises miR-125a and miR-125b with similar sequences. The miR-125 family has been reported to play a role in the initiation and progression of cancers by either acting as tumor suppressors or oncogenes (Cowden Dahl et al., 2009; Jiang et al., 2010). However, it is clear that miR-125a down-regulation is closely linked to the development of leukemia (Ufkin et al., 2014). MiR-125a is also found responsible in adipose tissue and immune development (Sun et al., 2009; Guo et al., 2010). MiR-125a targets and inhibits the expression of estrogen-related receptor alpha (ERRα), a nuclear receptor that plays an important role in a number of metabolic homeostasis processes, such as fatty acid metabolism (Huss et al., 2004; Ji et al., 2014). It was also found that miR-125a is overexpressed in diabetic rats as compared with non-diabetic ones (Herrera et al., 2009). Intriguingly, the overexpression of miR-125a has been found to inhibit adipocyte differentiation and the underlying gender-specific mechanisms of how miR-125a works together with ERRα requires further investigation (Herrera et al., 2009). Although the relationship of miR-125 and estrogen signaling in adipocytes has not been well established, estrogen is found to alter miR-125 family in other cell types. MiR-125b can be up-regulated by estrogen via ERα pathway, which thus protects against NAFLD in mouse hepatocytes by inhibiting fatty acid synthesis and preventing lipid accumulation in liver (Zhang et al., 2015) (Table 1).

miR-222
In a study of 3T3-L1 adipocytes, miR-222 was found upregulated when exposed to a high extracellular glucose concentration and in obese adipocytes (Xie et al., 2009; Herrera et al., 2010). High estradiol concentrations in visceral adipocytes were reported to increase miR-222 expression and decrease ERα and GLUT4 expression (Shi et al., 2014). Previous findings have also demonstrated the role of estrogen, androgen, and other hormones in insulin sensitivity (Livingstone and Collison, 2002; Retnakaran et al., 2010). High estrogen level can reduce insulin sensitivity by mediating ERα and ERβ (Barros et al., 2009). In vivo and in vitro studies indicated that a high concentration of estrogen could inhibit the expression of the insulin-sensitive transporter GLUT4 in adipose tissue, muscle, and liver (Campbell and Febbraio, 2002). ERα was also found to be a direct target of miR-222 in breast cancer cells, with a specific binding site at the seed sequence of miR-222 (Rao et al., 2011). miR-222 could be an important regulator of ERα expression in insulin resistance. However, a clearer pathway needs to be elucidated by further overexpression of miR-222 to determine whether it directly acts on ERα and GLUT4 expression (Shi et al., 2014). Possible signaling pathways of the action of miR-222 includes β-catenin and TGF-β signaling (Rao et al., 2011) (Table 1).

miR-301a
Preadipocytes can proliferate and differentiate into an adipose deposit upon stimulation and leads to an increase in adipocyte numbers and leading to obesity (Rosen and MacDougald, 2006). Although the relationship between preadipocyte infiltration and the initiation of HCC remains unclear, studies have shown that the recruitment of preadipocytes is responsible for enhancing prostate cancer invasion and breast cancer development (Rama-Esendagli et al., 2014; Xie et al., 2015). Preadipocytes were found to induce miR-301a to promote metastasis of prostate cancer by down-regulating AR (Xie et al., 2015). Down-regulation of AR could regulate translationally and increase TGF-β1 expression (Qi et al., 2008). Following the Smad signaling mediators, the down-regulation of AR consequentially activated target genes like matrix metallopeptidase 9 (MMP-9) and promote tumor metastasis (Derynck et al., 1998; Wang et al., 2013). Although AR overexpression was present in progressive HCC, AR was
TABLE 1 | Target genes, functions of sex hormone-associated miRNAs in adipocytes.

| miRNA | Expression in Obesity | Expression in T2D | Targets | Upstream | Functions | Reference |
|-------|-----------------------|-------------------|---------|----------|-----------|-----------|
| miR-125a | Up | Up | Inhibit ERα | ? | Inhibit adipocyte differentiation; Inhibit ERβ; Reduce insulin sensitivity | Huss et al., 2004; Herrera et al., 2009; Sun et al., 2009; Guo et al., 2010; Ji et al., 2014; Yeh et al., 2014 |
| miR-125b | Down | Down | ? | Up-regulated by ERα | Inhibit NAFLD; Inhibit lipid accumulation; Inhibit fatty acid synthesis | Xie et al., 2009; Ortega et al., 2010; Zhang et al., 2015 |
| miR-222 | Up | Up | Inhibit ERα, GLUT4 | Up-regulated by high glucose and estradiol | Reduce insulin sensitivity | Campbell and Febbraio, 2002; Livingstone and Collison, 2002; Xie et al., 2009; Herrera et al., 2010; Retnakaran et al., 2010; Rao et al., 2011; Shi et al., 2014; Deiulis, 2016 |
| miR-301a | ? | Up | Inhibit AR | ? | Promote metastasis; Increase TGF-β1 expression | Derynck et al., 1998; Qi et al., 2008; Panganui et al., 2013; Xie et al., 2015 |
| miR-375 | Down | Down | Inhibit ADIPOR2 | Induced by ERK-PPARγ-aP2 signaling; Inhibited by androgen | Promote fat accumulation; Reduce insulin sensitivity | Yamauchi et al., 2003; Krek et al., 2005; Bauer et al., 2010; Ling et al., 2011; Kraus et al., 2015 |

also found to be essential in suppressing HCC metastasis in the later stage of tumor development (Zender and Kubicka, 2008; Ma et al., 2012). A high AR expression could reduce the phosphorylation and inhibit the activity of p38, NF-κB signaling and MMP-9 expression and the suppress HCC metastasis (Tian et al., 2015). The coinciding evidence of miR-301a expression and AR signaling in preadipocytes in different cancer types may help understand the gender disparity of late-stage HCC progression (Table 1).

miR-375

The direct binding of miR-375 was mentioned to locate at the 3’UTR of murine and human ADIPOR2 (Krek et al., 2005; Kraus et al., 2015). ADIPOR2, as a receptor for adiponectin, mediates to increased PPARα ligand activities and fatty-acid oxidation by regulating adiponectin and ADIPOR2 signaling in adipose tissue (Yamauchi et al., 2003; Bauer et al., 2010). The function of miR-375 was reported to be induced during adipogenesis and to promote adipocyte differentiation by suppressing ERK1/2 phosphorylation via the ERK-PPARγ-aP2 signaling (Ling et al., 2011). Insulin resistance in adipocytes was associated with a low adiponectin receptor level (Bauer et al., 2010). Increased expression levels of both ADIPOQ and ADIPOR2 could help prevent fat accumulation in liver and adipose tissue and led to increased insulin sensitivity (Ma and Liu, 2013). Studies also showed that the expressions of adipogenesis-promoting miR-375 and ADIPOR2 were decreased and increased, respectively, in androgen treatment (Kraus et al., 2015). Inhibiting miR-375 could decrease adipocyte differentiation and increase ADIPOR2 protein expression (Kraus et al., 2015). From the observations in separate studies, miR-375 may be responsible for the deterioration of insulin-resistance-related liver injury and may cause the difference in the visceral fat deposition and liver diseases in men and women when the body androgen level decreases with age (Bassil et al., 2009) (Table 1).

Emerging epigenetic studies in adipocytes reveal a range of regulatory mechanisms in adipogenesis, adipokine expression and other metabolic pathways. Although limited studies have been done in the epigenetic regulations in adipocytes to demonstrate gender dimorphisms, AR and ER have already been shown to alter the epigenetic profiles as a nuclear factor in HCC cells (Li et al., 2012). Our body fat composition may as well be regulated epigenetically and lead to such gender disparities. The epigenetic mechanisms in adipocytes may provide insights in HCC development through metabolic deregulation. With the advancement of the nuclei capture technique in VAT and SCAT mentioned by Ambati et al. (2016) it will be promising to study the depot-specific and even gender-specific epigenetic profiles in adipocytes to unveil the underlying mechanisms in adipocyte homeostasis and its potential effects on HCC initiation.

GENDERS, AQUAGLYCEROPORINS and HCC

Glycerol-3-phosphate (G3P), which is also known as glycerol, is an important metabolite for the control of fat accumulation and is the responsible for triacylglycerols (TAGs) synthesis and glucose homeostasis. Circulating free glycerol results from lipolysis, diets or in the kidney reabsorption (Reshef et al., 2003). Aquaglyceroporins (AQP) are protein channels for the transport of glycerol, other small neutral solutes and water across adipocytes. AQP are emerging as important players adipocyte homeostasis implicated with adiposity and the control of insulin resistance (Rojek et al., 2007). Aquaglyceroporins are sub-classified into AQPs, 7, 9, and 10 which regulate transport of
glycerol and insulin sensitivity in adipocytes (Frühbeck, 2005). In line with the gender dimorphisms in glucose and fat metabolism, the different expressions of AQPs and glycerol transport in men and women are also observed in diet-induced diseases including insulin resistance and NAFLD (Rodríguez et al., 2006; Rojek et al., 2007).

Regarding the relationship between AQPs and HCC, emerging evidence has also been ascribing AQP deregulation in hepatocytes to the pathogenesis and, as well, the metastasis of NAFLD-associated HCC. AQP9 has been identified as an important glycerol transport pathway in hepatocytes to facilitate hepatic gluconeogenesis and TAG synthesis (Rodríguez et al., 2011a). AQP9 is the main aquaglyceroporin in the liver and is dramatically reduced in HCC and is localized at non-tumorigenic liver tissue (Padma et al., 2009; Ribatti et al., 2014; Chen et al., 2016). AQP9 knockdown in mice significantly alleviated NAFLD-related symptoms including intrahepatic lipid accumulation and high serum lipid level, possibly due to a decrease in glycerol import into hepatocytes thus reducing liver lipid accumulation (Cai et al., 2013). The results are controversial since the resulted AQP9 knockdown is not tissue-specific and a global effect of AQP9 is observed, including glycerol absorption. However, AQP9 down-regulation was found frequent in hepatic biopsies of obese patients with type 2 diabetes (Catalán et al., 2008). A reduced AQP9 expression in HCC cells was shown to resist apoptosis and the respective overexpression could restore the cell responsiveness to apoptotic stimuli (Jablonski et al., 2007). Protein kinase A activator, dibutyryl cAMP, increased AQP9 expression in HCC cells and suppressed tumor growth in vivo, suggesting the important roles of hepatocyte AQP9 in HCC development (Peng et al., 2016). Experiments in the SMMC7721 cell line demonstrated the molecular mechanism of AQP overexpression on its tumor suppressive function. An increase in AQP9 expression repressed the PI3K/Akt pathway and thus increased forkhead box protein O1 expression and up-regulation of apoptotic caspase-3 (Li et al., 2016; Zhang Q. et al., 2016). AQP9 downregulation also promoted HCC metastasis in mice (Zhang Q. et al., 2016). The observed down-regulation of AQP9 in hepatocytes in obesity, diabetes and HCC is believed to be a negative feedback response of high glycerol intake. AQP9 is important in controlling glycerol import in hepatocytes. A proper glycerol import is crucial in maintaining the gluconeogenic pathway in hepatocytes and a normal lipid metabolism in the surrounding adipose tissues. The up-regulation hepatic AQP9 expression was associated with the alleviation the NAFLD-associated symptoms (Rodríguez et al., 2015b). AQP9 in hepatocytes is considered to offer a protective effect on HCC initiation and metastasis. On top of the clear relationship between hepatocyte AQPs with HCC, the interactions between adipocytes and hepatocytes are crucial in studying NAFLD-related HCC development since the distinguishing difference in fat deposition in males and females also affect glycerol transport and the corresponding subsequences. The coinciding gender dimorphism in fat metabolism and HCC development show the prospect in the interrelation between adipocyte and hepatocyte homeostasis.

In adipocytes, AQP7 acts as the main pathway in facilitating release of glycerol, while the others, including AQP3, 10 and 11 contribute glycerol export to a lower extent (Rodríguez et al., 2011a; Laorenza et al., 2013; Madeira et al., 2014). The expression of AQPs also appears to be location-specific. Visceral adipocytes exhibit a higher expression level of AQP3 and AQP7, which may result in the overall rise in the lipolytic rate and glycerol release from VAT (Miranda et al., 2010; Rodríguez et al., 2015a). In contrast, subcutaneous fat with a lower AQP7 level may help promote glycerol accumulation and thus adipocyte hypertrophy (Rodríguez et al., 2015a). AQP regulation in adipocytes is crucial in maintaining the fat and glucose homeostasis, i.e., a deregulation will lead to obesity and insulin resistance (Kuriyama et al., 2002; Hibuse et al., 2005).

A higher plasma glycerol level can be observed in females, which can be explained by a higher body fat rate resulting in a faster glycerol turnover (Hedrington and Davis, 2015). Moreover, adipose tissues respond differently to adipokines, lipolytic hormones and probably sex hormones in men and women (Schmidt et al., 2014). Fasting studies and exercise studies have shown that women exhibit a significantly higher glycerol level than men, which may be ascribed to the differences in sensitivity to insulin, epinephrine, leptin and even neural activities (Clère et al., 1989; Davis et al., 2000; Frühbeck et al., 2001, 2014; Hedrington and Davis, 2015). Obesity is associated with a higher lipolytic rate, plasma FFAs and glycerol (Rodríguez et al., 2015a). A gender-specific effect of regular exercise has shown a higher expression of omental adipose AQP7 in females (Rodríguez et al., 2015a).

Besides differential AQP expression, gender dimorphisms also occur in the response to leptin. The adipokine leptin has a lipolytic activity and has been shown to repress AQP7 and AQP9 expression via the PI3K/Akt/mTOR signaling pathway in human adipocytes (Rodríguez et al., 2011b). The association between a higher expression of AQP7 in females and the leptin level requires further investigation (Sjöholm et al., 2005; Dahlhoff et al., 2014). Leptin stimulates translocation of AQP7 to the cytoplasm to facilitate glycerol release from adipocytes (Rodríguez et al., 2015b). At the same time leptin can also downregulate AQP7 mRNA to prevent depletion of fat stores (Rodríguez et al., 2015b). Long-term leptin administration in male leptin-deficit mice could downregulate AQP3 and AQP7 and could help alleviate lipid accumulation in adipose tissue and liver (Rodríguez et al., 2011b, 2015b). However, the miscellaneous functions of leptin contradict in the development of obesity and liver cancer (Rodríguez et al., 2015b). The rescuing effect of leptin in NAFLD in leptin-deficient obese mice could be due to the neuroactive effects of leptin, but not as adipokines promoting local inflammation around internal organs. AQP7 is downregulated in women with severe obesity and this trait is limited to obesity but not type 2 diabetes (Ceperuelo-Mallafré et al., 2007). The downregulation of AQP7 was also reported to increase susceptibility of obesity by promoting lipid accumulation in the adipose tissue (Marrades et al., 2006). The complicated association between NAFLD and AQPs involves not only adipocyte glycerol transport, but also the glucose and glycerol transport in hepatocytes. Mechanistic delineation of leptin in adipocytes is required to elucidate its relationship with liver cancer initiation.
CONCLUDING REMARKS

Deregulated energy homeostasis and metabolic disorders induced by obesity and type 2 diabetes are key but largely unresolved issues in HCC development. The alterations in genetic, epigenetic and miRNA control of lipid and glucose metabolism, oxidative stress and the production of pro-inflammatory and anti-inflammatory cytokines contribute to the multiple-step development of NAFLD, NASH, cirrhosis and eventually HCC. The increased incidence of HCC associated with metabolic syndrome is significantly associated with the male gender. Sexual dimorphism as exemplified by the androgen and estrogen signaling pathways shapes the fat distribution in the body, contributing to the differential exposure to pro-inflammatory cytokines and lipotoxic adipokines which influence hepatic malignant transformation. Further mechanistic delineation of adipocyte metabolism via sex hormones using systems approach will shed light on the multifaceted roles of aberrant fat accumulation in HCC initiation and progression.

AUTHOR CONTRIBUTIONS

All authors listed have made substantial, direct and intellectual contribution to the work, and approved it for publication.

ACKNOWLEDGMENTS

This work was supported by the Collaborative Research Fund (C4017-14G), General Research Fund (CUHK14102914), Health and Medical Research Fund (03141376), National Natural Science Foundation of China (373492) and Focused Investment Scheme (1907301). AC is supported by funding from the Young Researcher Award, the Chinese University of Hong Kong.

REFERENCES

Allard, C., Desgagné, V., Patenaude, J., Lacroix, M., Guilemette, L., Battista, M. C., et al. (2015). Mendelian randomization supports causality between maternal hyperglycemia and epigenetic regulation of leptin gene in newborns. Epigenetics 10, 342–351. doi: 10.1080/15592294.2015.1029700
Ambati, S., Yu, P., Mckinney, E. C., Kandasamy, M. K., Hartzell, D., Baile, C. A., et al. (2016). Adipocyte nuclei captured from VAT and SAT. BMC Obes. 3:35. doi: 10.1186/s40608-016-0112-6
Arner, P., Sinha, I., Thorell, A., Rydén, M., Dahlman-Wright, K., and Dahlman, I. (2015). The epigenetic signature of subcutaneous fat cells is linked to altered expression of genes implicated in lipid metabolism in obese women. Clin. Epigen. 7:93. doi: 10.1186/s13148-015-0126-9
Bafy, G., Brunet, E. M., and Caldwell, S. H. (2012). Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J. Hepatol. 56, 1384–1391. doi: 10.1016/j.jhep.2011.10.027
Barros, R. P., Gabbi, C., Morani, A., Warner, M., and Gustafsson, J. A. (2009). Participation of ERα and ERβ in glucose homoeostasis in skeletal muscle and white adipose tissue. Am. J. Physiol. Endocrinol. Metab. 297, E124–E133. doi: 10.1152/ajpendo.00189.2009
Bassil, M., Alkaade, S., and Morley, J. E. (2009). The benefits and risks of hormones using systems approach will shed light on the mechanistic delineation of adipocyte metabolism via sex hormones using systems approach will shed light on the

Birnholz, D. (2012). Targeting angiogenesis as treatment for obesity. Arterioscler. Thromb. Vasc. Biol. 32, 161–162. doi: 10.1161/ATVBAHA.111.241992
Bruun, J. M., Lihn, A. S., Pedersen, S. B., and Richelsen, B. (2005). Monocyte chemoattractant Protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J. Clin. Endocrinol. Metab. 90, 2282–2289. doi: 10.1210/jc.2004-1696
Caba, B., Andrade, S., Carreira, M. C., Casanueva, F. F., and Crujeiras, A. B. (2016). A role for novel adipose tissue-secreted factors in obesity-related carcinogenesis. Obes. Rev. 17, 361–376. doi: 10.1111/obr.12377
Cai, C., Wang, C., Ji, W., Liu, B., Kang, Y., Hu, Z., et al. (2013). Knockdown of hepatic aquaglyceroporin-9 alleviates high fat diet-induced non-alcoholic fatty liver disease in rats. Int. Immunopharmacol. 15, 550–556. doi: 10.1016/j.intimp.2013.01.020
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., and Thun, M. J. (2003). Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 348, 1625–1638. doi: 10.1056/NEJMoa021423
Campbell, S. E., and Feibbraio, M. A. (2002). Effect of the ovarian hormones on GLUT4 expression and contraction-stimulated glucose uptake. Am. J. Physiol. Endocrinol. Metab. 282, E1139–E1146. doi: 10.1152/ajpendo.00814.2001
Catalán, V., Gómez-Ambrosi, J., Pastor, C., Rotellar, F., Silva, A. C., Rodríguez, A., et al. (2009). Influence of morbim obesity and insulin resistance on gene expression levels of AQP7 in visceral adipose tissue and AQP9 in liver. Obes. Surg. 18, 695–701. doi: 10.1007/s11695-008-9453-7
Ceperuelo-Mallafré, V., Miranda, M., Chacón, M. R., Vilarrasa, N., Megia, A., Gutierrez, C., et al. (2007). Adipose tissue expression of the glycerol channel

Bird, A. (2002). DNA methylation patterns and epigenetic memory. Genes. Dev. 16, 6–21. doi: 10.1101/gad.947102
Björntorp, P. (1995). Endocrine abnormalities in obesity. Metabolism. 44(9 Suppl. 3), 21–23. doi: 10.1002/0026-0495(95)90315-1
Blüher, M. (2009). Adipose tissue dysfunction in obesity. Exp. Clin. Endocrinol. Diabetes 117, 241–250. doi: 10.1055/s-0029-1192044
Bostrom, M. A., Freedman, B. I., Langefeld, C. D., Liu, L., Hicks, P. J., and Bowden, D. W. (2009). Association of adiponectin gene polymorphisms with type 2 diabetes in an African American population enriched for nephropathy. Diabetes Metab. Res. Rev. 58, 499–504. doi: 10.2337/db08-0598
Bouchard, L., Tchernof, A., Deshaies, V., Marceau, S., Lescelleur, O., Biron, S., et al. (2007). ZFP36a promoting candidate gene for obesity-related metabolic complications identified by converging genomics. Obes. Surg. 17, 372–382. doi: 10.1007/s11695-007-9067-5
Bray, F., Ren, J. S., Masuyer, E., and Ferlay, J. (2013). Estimates of global cancer prevalence for 27 sites in the adult population in 2008. Int. J. Cancer 132, 1133–1145. doi: 10.1002/ijc.27711
Bruummer, D. (2012). Targeting angiogenesis as treatment for obesity. Arterioscler. Thromb. Vasc. Biol. 32, 161–162. doi: 10.1161/ATVBAHA.111.241992
Buishand, A. A., Klimstra, S. D., van der Burg, M. J. G., and van Diest, P. J. (2003). Ultrastructural alterations in micropapillary carcinoma of the breast. Histol. Histopathol. 18, 469–476.
Breuing, A., Johnstone, A., Eccles, D., Harmon, B., Hayes, M. T., Lea, R. A., et al. (2013). An analysis of DNA methylation in human adipose tissue reveals differential modification of obesity genes before and after gastric bypass and weight loss. Genome. Biol. 16:8. doi: 10.1186/1368-899X-16-8
apocynin-7 gene is altered in severe obesity but not in type 2 diabetes. J. Clin. Endocrinol. Metab. 92, 3640–3645. doi: 10.1210/jc.2007-0531

Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., et al. (2012). The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 55, 2005–2023. doi: 10.1016/j.gastro.2012.05.046

Chang, Y., Jung, H. S., Cho, J., Zhang, Y., Yun, K. E., Lazo, M., et al. (2016). Metabolically healthy obesity and the development of nonalcoholic fatty liver disease. Am. J. Gastroenterol. 111, 1133–1140. doi: 10.1038/ajg.2016.178

Chatterjee, T. K., Basford, J. E., Yiew, K. H., Stepp, D. W., Hui, D. Y., and Weintraub, N. L. (2014). Role of histone deacetylase 9 in regulating adipogenic differentiation and high fat-diet induced metabolic disease. Adipocyte 3, 333–338. doi: 10.4161/adip.28814

Chatterjee, T. K., Idelman, G., Blanco, V., Blomkalns, A. L., Pieger, M. G. Jr., Weintraub, D. S., et al. (2011). Histone deacetylase 9 is a negative regulator of adipogenic differentiation. J. Biol. Chem. 286, 27836–27847. doi: 10.1074/jbc.M111.262964

Chen, C., Chang, Y. C., Liu, C. L., Liu, T. P., Chang, K. J., and Guo, I. C. (2007). Leptin induces proliferation and anti-apoptosis in human hepatocarcinoma cells by up-regulating cyclin D1 and down-regulating Bax via a Janus kinase 2-linked pathway. Endocr. Relat. Cancer 14, 513–529. doi: 10.1677/ERC-06-0057

Chen, M. J., Yeh, Y. T., Lee, K. T., Tsai, C. J., Lee, H. H., and Wang, S. N. (2012). The promoting effect of adiponectin in hepatocellular carcinoma. J. Surg. Oncol. 106, 181–187. doi: 10.1002/jso.23059

Chen, X., Li, C., Lü, L., and Mei, Z. (2016). Expression and clinical significance of aquaglyceroporins in human hepatocellular carcinoma. Mol. Med. Rep. 13, 5283–5289. doi: 10.3892/mmr.2016.5184

Clare, J. N., Glickman, P. S., Helm, S. T., Nestler, J. E., and Blackard, W. G. (1989). Accelerated decline in hepatic glucose production during fasting in normal women compared with men. Metabolism 38, 1103–1107. doi: 10.1016/0026-0495(89)90047-4

Crowden, D., 2013). The immune cells in adipose tissue. Diabetologia 56, 25762

Dahl, M., Pfister, S., Blutke, A., Rozman, J., Klingenspor, M., Deutsch, Jr., Weintraub, D. S., et al. (2011). Histone deacetylase 9 is a negative regulator of adipogenic differentiation. J. Biol. Chem. 286, 27836–27847. doi: 10.1074/jbc.M111.262964

Doll, R., Zhang, Y., and Fung, X. H. (1999). Snaps: transcriptional activators of TGF-beta responses. Cell 95, 737–740. doi: 10.1016/S0092-8674(00)81696-7

Doll, R., Zhang, Y., and Fung, X. H. (1999). Snaps: transcriptional activators of TGF-beta responses. Cell 95, 737–740. doi: 10.1016/S0092-8674(00)81696-7

Dolley, G., Bertrais, S., Frochot, V., Bebel, J. F., Guerre-Millo, M., Tores, F., et al. (2002). Promoter adiponectin polymorphisms and waist/hip ratio variation in a prospective French adults study. Int. J. Obes. (Lond.) 32, 669–675. doi: 10.1038/sj.ijo.0803773

Duan, X. F., Tang, P., Li, Q., and Yu, Z. T. (2013). Obesity, adipokines and hepatocellular carcinoma. Int. J. Cancer 133, 1776–1783. doi: 10.1002/ijc.28105

El-Serag, H. B. (2012). Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142, 1264–1273. doi: 10.1053/j.gastro.2011

ENCODE Project Consortium (2012). An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57–74. doi: 10.1038/nature11247

Esteller, M. (2007). Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 8, 286–298. doi: 10.1038/nrg2005

Fairfax, B. P., Makino, S., Radhakrishnan, J., Plant, K., Leslie, S., Dilthey, A., et al. (2012). Genetics of gene expression in primary immune cells identifies cell type-specific master regulators and roles of HLA alleles. Nat. Genet. 44, 502–510. doi: 10.1038/ng.2520

Farazi, P. A., and DePinho, R. A. (2006). Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 6, 674–687. doi: 10.1038/nrc1934

Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359–E386. doi: 10.1002/ijc.29210
Isobe, T., Saitoh, S., Takagi, S., Takeuchi, H., Chiba, Y., Katoh, N., et al. (2016). Sex differences in immune responses. Nat. Rev. Immunol. 16, 1099–1109. doi: 10.1038/nri.2016.0061

Kuriyama, H., Shimomura, I., Kishida, K., Kondo, H., Furuyama, N., Nishizawa, H., et al. (2002). Coordinated regulation of fat-specific and liver-specific glyceral channels, aquaporin adipose and aquaporin 9. Diabetes 51, 2915–2921.

Kuroda, M., Tominaga, A., Nakagawa, K., Nishiguchi, M., Sebe, M., Miyatate, Y., et al. (2016). DNA methylation suppresses leptin gene in T3–L1 adipocytes. PLoS ONE 11:e0160532. doi: 10.1371/journal.pone.0160532

Laforenza, U., Scaffino, M. F., and Gastroli, G. (2013). Aquaporin-10 represents an alternative pathway for glycerol efflux from human adipocytes. PLoS ONE 8:e54474. doi: 10.1371/journal.pone.0054474

Lee, P. C., Ziegler, A. R., and Sehgal, A. R. (2013). The leptin receptor promotes adipocyte differentiation in vitro and in vivo. Mol. Cell. Endocrinol. 375, 79–92. doi: 10.1016/j.mce.2013.08.008

Lim, L. S., Cheung and Cheng Genders, Adipocyte Metabolism and HCC in vivo gene expression and leptin secretion in rat
Rodríguez, A., Catalán, V., Gómez-Ambrosi, J., and Frühbeck, G. (2011a). Aquaglyceroporins serve as metabolic gateways in adiposity and insulin resistance control. Cell Cycle 10, 1548–1556. doi: 10.4161/cc.10.19.15672

Rodríguez, A., Catalán, V., Gómez-Ambrosi, J., García-Navarro, S., Rotellar, F., Valenti, V., et al. (2011b). Insulin- and leptin-mediated control of aquaglyceroporins in human adipocytes and hepatocytes is mediated via the PI3K/Akt/mTOR signaling cascade. J. Clin. Endocrinol. Metab. 96, E586–E597. doi: 10.1210/endo.2010-1408

Rodríguez, A., Marinelli, R. A., Tese, A., Frühbeck, G., and Calamita, G. (2015a). Sexual dimorphism of adipose and hepatic aquaglyceroporins in health and metabolic disorders. Front. Endocrinol. 6:171. doi: 10.3389/fendo.2015.00171

Rodríguez, A., Moreno, N. R., Balagué, L., Méndez-Giménez, L., Becerril, S., Catalán, V., et al. (2015b). Leptin administration restores the altered adipose and hepatic expression of aquaglyceroporins improving the non-alcoholic fatty liver of ob/ob mice. Sci. Rep. 5:21267. doi: 10.1038/srep21267

Rojek, A. M., Skowronska, M. T., Füchtbauer, E. M., Füchtbauer, A. C., Fenton, R. A., Agre Freikier, J., et al. (2007). Defective glycerol metabolism in aquaporin 9 (AQP9) knockout mice. Proc. Natl. Acad. Sci. U.S.A. 104, 3609–3614. doi: 10.1073/pnas.0610894104

Rönn, T., Volkov, P., Davegårdh, C., Dayeh, T., Hall, E., Olsson, A. H., et al. (2013). A six month exercise intervention influences the genome-wide DNA methylation pattern in human adipose tissue. PLoS Genet. 9:e1003572. doi: 10.1371/journal.pgen.1003572

Rodríguez, A., Catalán, V., Gómez-Ambrosi, J., García-Navarro, S., Rotellar, F., Valenti, V., et al. (2011b). Insulin- and leptin-mediated control of aquaglyceroporins in human adipocytes and hepatocytes is mediated via the PI3K/Akt/mTOR signaling cascade. J. Clin. Endocrinol. Metab. 96, E586–E597. doi: 10.1210/endo.2010-1408

Rodríguez, A., Moreno, N. R., Balagué, L., Méndez-Giménez, L., Becerril, S., Catalán, V., et al. (2015b). Leptin administration restores the altered adipose and hepatic expression of aquaglyceroporins improving the non-alcoholic fatty liver of ob/ob mice. Sci. Rep. 5:21267. doi: 10.1038/srep21267

Sharma, D., Wang, J., Fu, P. P., Sharma, S., Nagalingam, A., Mells, J., et al. (2010). Adiponectin antagonizes the oncogenic actions of leptin in hepatic cell carcinoma. Hepatology 52, 1713–1722. doi: 10.1002/hep.23892

Sun, T., Fu, M., Bookout, A. L., Kliever, S. A., and Mangelsdorf, D. J. (2009). MicroRNA let-7 regulates T3-L1 adipogenesis. Mol. Endocrinol. 23, 925–931. doi: 10.1210/me.2008-0298

Sung, Y. J., Pérezus, L., Sarzynski, M. A., Fornage, M., Sidney, S., Sternfeld, B., et al. (2016). Genome-wide association studies suggest sex-specific loci associated with abdominal and visceral fat. Int. J. Obes. 40, 662–674. doi: 10.1038/ijo.2015.217

Tian, Y., Wong, V. W., Chan, H. L., and Cheng, A. S. (2013). Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. Sem. Cancer Biol. 23(6 Pt B), 471–482. doi: 10.1016/j.semcancer.2013.08.010

Tian, Y., Xie, X. U., Lin, Y., Tan, G., and Zhong, W. U. (2015). Androgen receptor in hepatocarcinogenesis: recent developments and perspectives. Oncol. Lett. 9, 1983–1988. doi: 10.3892/ol.2015.3025

Tinaikos, D. G., Vos, M. B., and Brunt, E. M. (2010). Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu. Rev. Pathol. 5, 145–171. doi: 10.1146/annurev-pathol-121808-102132

Tobi, E. W., Lumey, L. H., Talens, R. P., Kremer, D., Putter, H., Stein, A. D., et al. (2009). DNA methylation differences after exposure to prenatal famine are common and timing and sex-specific. Hum. Mol. Genet. 18, 4046–4053. doi: 10.1093/hmg/ddp353

Trayhurn, P., Wang, B., and Wood, I. S. (2008). Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity. Br. J. Nutr. 100, 227–235. doi: 10.1017/S0007114508071282

Trayhurn, P., and Wood, I. S. (2004). Adipokines: inflammation and pleiotropic role of white adipose tissue. Br. J. Nutr. 92, 347–355. doi: 10.1079/BJN200404121

Tsai, E. C., Matsumoto, A. M., Fujimoto, W. Y., and Boyko, E. J. (2004). Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormone-binding globulin and body fat. Diabetes Care 27, 861–868. doi: 10.2337/diacare.27.4.861

Tsachizoi, E., Papaioannou, G. V., Hadziyannis, E., Georgiou, A., Kafri, G., Tinaikos, D. G., et al. (2008). Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scand. J. Gastroenterol. 43, 1128–1136. doi: 10.1080/00365520802085387

Tworoger, S. S., Manzoros, C., and Hankinson, S. E. (2007). Relationship of plasma adiponectin with sex hormone and insulin-like growth factor levels. Obesity (Silver Spring) 15, 2217–2224. doi: 10.1038/oby.2007.263

Ulfkin, M. L., Peterson, S., Yang, X., Driscoll, H., Duarte, C., and Sathyanarayana, P. (2014). miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia. Leuk. Res. 38, 402–410. doi: 10.1016/j.leukres.2013.12.021

Villanueva, A., and Llovet, J. M. (2014). Liver cancer in 2013: mutational landscape of HCC-the end of the beginning. Nat. Rev. Clin. Oncol. 11, 73–74. doi: 10.1038/nrclinonc.2013.243

Vongsvanh, R., George, J., Qiao, L., and van der Poorten, D. (2012). Visceral adiposity in gastrointestinal and hepatic carcinogenesis. Cancer Lett. 330, 1–10. doi: 10.1016/j.canlet.2012.11.038

Wachter, C. S., and Frühbeck, G. (2011a). MicroRNA let-7 regulates T3-L1 adipogenesis. Mol. Endocrinol. 23, 925–931. doi: 10.1210/me.2008-0298

Wang, T., Ma, X., Peng, D., Zhang, R., Sun, X., Chen, M., et al. (2016). Effects of obesity related genetic variations on visceral and subcutaneous fat distribution in a Chinese population. Sci. Rep. 6, 20691. doi: 10.1038/srep20691

Wang, X., Lee, S. O., Xia, S., Jiang, Q., Luo, J., Li, L., et al. (2013). Endothelial cells enhance prostate cancer metastasis via IL-6–androgen receptor–TGF-β→MMP-9 signals. Mol. Cancer Ther. 12, 1026–1037. doi: 10.1158/1535-7163.MCT-12-0895
Watanabe, N., Takai, K., Imai, K., Shimizu, M., Naiki, T., Nagaki, M., et al. (2011). Increased levels of serum leptin are a risk factor for the recurrence of stage II hepatocellular carcinoma after curative treatment. *J. Clin. Biochem. Nutr.* 49, 153–158. doi: 10.3164/jcbn.10-149

Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L., and Ferrante, A. W., Jr. (2003). Obesity is associated with macrophage accumulation in adipose tissue. *J. Clin. Invest.* 112, 1796–1808. doi: 10.1172/JCI19246

Welzel, T. M., Graubard, B. I., Quraishi, S., Zeuzem, S., Davila, J. A., El-Serag, H. B., et al. (2013). Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. *Am. J. Gastroenterol.* 108, 1314–1321. doi: 10.1038/ajg.2013.160

Wieckowska, A., Papouchado, B. G., Li, Z., Lopez, R., Zein, N. N., and Watanabe, N., Takai, K., Imai, K., Shimizu, M., Naiki, T., Nagaki, M., et al. (2011). Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. *Nature* 499, 97–101. doi: 10.1038/nature12347

Xiu, H., Li, L., Zhu, G., Dang, Q., Ma, Z., He, D., et al. (2015). Infiltrated tissue cytokines in metabolic disorders linked to obesity. *J. Am. Soc. Nephrol.* 26, 2792–2800. doi: 10.1097 ASN.0000141966.69934.21

Xie, H., Li, L., Zhu, G., Dang, Q., Ma, Z., He, D., et al. (2015). Infiltrated adipocytes increase prostate cancer metastasis via modulation of the miR-301a/androgen receptor (AR)/TGF-β1/Smad/MMP9 signals. *Oncotarget* 6, 12326–12339. doi: 10.18632/oncotarget.3619

Xie, H., Lim, B., and Lodish, H. F. (2009). MicroRNAs induced furing adipogenesis that accelerate fat cell development are downregulated in obesity. *Diabetes Metab. Res. Rev.* 58, 1050–1057. doi: 10.2337/db08-1299

Yamauchi, T., Kamon, J., Ito, Y., Tsuchida, A., Yokomizo, T., Kita, S., et al. (2003). Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. *Nature* 423, 762–769. doi: 10.1038/nature01705

Yang, W., Lu, Y., Xu, Y., Xu, L., Zheng, W., Wu, Y., et al. (2012). Estrogen represses hepatocellular carcinoma (HCC) growth via inhibiting alternative activation of tumor-associated macrophages (TAMs). *J. Biol. Chem.* 287, 40140–40149. doi: 10.1074/jbc.M112.348763

Yeh, C. L., Cheng, I. C., Hou, Y. C., Wang, W., and Yeh, S. L. (2014). MicroRNA-125a-3p expression in abdominal adipose tissue is associated with insulin signaling gene expressions in morbid obesity: observations in Taiwanese, Asia. *Pac. J. Clin. Nutr.* 23, 331–337. doi: 10.6133/apcn.2014.23.2.20

Zhang, Q., Xu, D., Zhang, M., Dong, X., Dong, H., and Pan, Q. (2016). Construction and analysis of an adipose tissue-specific and methylation-sensitive promoter of leptin gene. *Appl. Biochem. Biotechnol.* doi: 10.1007/s12010-016-2162-0 [Epub ahead of print].

Zhang, W., Li, C., Liu, M., Chen, X., Shuai, K., Kong, X., et al. (2016). Aquaporin 9 is down-regulated in hepatocellular carcinoma and its over-expression suppresses hepatoma cell invasion through inhibiting epithelial-to-mesenchymal transition. *Cancer Lett.* 378, 111–119. doi: 10.1016/j.canlet.2016.05.021

Zhang, Z. C., Liu, Y., Xiao, L. L., Li, S. F., Jiang, J. H., Zhao, Y., et al. (2015). Upregulation of miR-125b by estrogen protects against non-alcoholic fatty liver in female mice. *J. Hepatol.* 63, 1466–1475. doi: 10.1016/j.jhep.2015.07.037

Zhao, J., and Lawless, M. W. (2013). Stop feeding cancer: pro-inflammatory role of visceral adiposity in liver cancer. *Cytokeine* 64, 626–637. doi: 10.1016/j.ctyto.2013.09.009

Zhou, Y., Peng, J., and Jiang, S. (2014). Role of histone acetyltransferases and histone deacetylases in adipocyte differentiation and adipogenesis. *Eur. J. Cell. Biol.* 93, 107–107. doi: 10.1016/j.ejcb.2014.03.001

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Cheung and Cheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.